Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.45 |
| ▸ | SENP2 | Q9HC62 | 7/20 | 0.61 |
| ▸ | SUMO2 | P61956 | 5/20 | 0.61 |
| ▸ | SUMO1 | P63165 | 5/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.61 |
| ▸ | ATIC | P31939 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.54 |
| ▸ | SENP1 | Q9P0U3 | 5/20 | 0.50 |
| ▸ | SENP3 | Q9H4L4 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258103 | 0.99 | SENP2 (0.62) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL13152004 | 0.98 | SENP2 (0.64) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL11655955 | 0.98 | SENP2 (0.64) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL17284072 | 0.91 | SENP2 (0.56) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL14388325 | 0.87 | ENPP2 (0.54) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL13265206 | 0.87 | ALDH1A1 (0.59) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL10393442 | 0.86 | SENP2 (0.77) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL17681933 | 0.85 | SENP2 (0.56) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL23258011 | 0.85 | ENPP2 (0.57) | SENP2SUMO2SUMO1SENP7ATIC | |
| SCHEMBL15386712 | 0.85 | SENP2 (0.58) | SENP2SUMO2SUMO1SENP7ATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102424-A1 | METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1 | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-16 | — | — | US | disclosed |
| US-12458660-B2 | Methods of attenuating an immune response by inhibition of BFL1 | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230131243-A1 | METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1 | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-04-27 | — | — | US | disclosed |
| US-11541073-B2 | Methods of attenuating an immune response by inhibition of BFL1 | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458660-B2 | Methods of attenuating an immune response by inhibition of BFL1 | CD74, IRF3, IRF2BP2 | THRB 4032/4885SENP2 1162/4885SUMO2 347/4885 |
| US-20230131243-A1 | METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1 | CD74, IRF3, IRF2BP2 | THRB 4032/4885SENP2 1162/4885SUMO2 347/4885 |
| US-11541073-B2 | Methods of attenuating an immune response by inhibition of BFL1 | CD74, IRF3, IRF2BP2 | THRB 4032/4885SENP2 1162/4885SUMO2 347/4885 |
| US-20260102424-A1 | METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1 | BCL2L1, TMBIM6, BET1 | THRB 3493/4885SENP2 3193/4885SUMO2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.